Phibro Animal Health just reported fiscal Q3 results that beat on both top and bottom lines — and promptly raised full-year guidance — yet the CEO has spent the past two weeks trimming his position into every bounce.
The earnings print landed after the close on May 6. Adjusted EPS of $0.76 cleared the $0.71 consensus. Revenue of $383.5M beat the $367M estimate by 4.5%. Full-year adjusted EPS guidance moved up to $2.98–$3.10 from $2.93–$3.10, and sales guidance edged higher to $1.46B–$1.50B. The GAAP EPS guidance raise was more emphatic — floor up from $2.08 to $2.25, ceiling up to $2.44. The numbers are unambiguously good. The stock's reaction will be watched closely when it trades on May 7.
The CEO selling is the harder thing to reconcile. Jack Bendheim, who holds approximately 48% of the company and doubles as founder-family patriarch, sold across ten separate transactions between April 22 and April 30 — totalling roughly $1.5M in proceeds at prices between $52.65 and $56.69. The 90-day net is positive at $5.4M sold across 98,560 net shares. None of the individual transactions are enormous relative to his position, and scheduled selling plans are common at this kind of concentrated-ownership company. Still, the cadence — nearly every trading day for a week — into a stock trading near its 3-month high is worth noting ahead of a print the Street was broadly watching.
Options positioning had been tilting more defensive into the results. The put/call ratio hit 1.78 on May 5, running above its 20-day average of 1.56 and sitting about 1.3 standard deviations above that mean. That's not an extreme reading — the 52-week high is 2.23 — but the drift higher through late April (the ratio was closer to 1.30 in mid-April) reflected growing caution among options traders as the earnings date approached. Short interest at 6.2% of free float is a real but not extreme level. It ticked up about 5.5% over the past month, with the sharpest step-up visible around April 23 when estimated short shares jumped from roughly 1.18M to 1.26M. Cost to borrow has been falling sharply — down 47% over 30 days to 0.43% — and availability in the lending market is relatively comfortable given the stock's size. The setup heading into the print was: modest but building short-side interest, manageable borrow costs, and options traders paying up for protection.
The Street's current read is mixed. Citigroup initiated coverage on April 15 with a Neutral rating and a $62 target — the most recent and freshest data point, and notably the only firm with a target above the current $56.24 price. The consensus sits at Hold across three covering analysts with a mean target of $51.20, which is now below where the stock trades. That inversion — stock above consensus target — is partly a function of the stock's move rather than analysts turning negative. JPMorgan carried an Overweight with a $50 target as of November 2025, and B of A maintained an Underperform with a $27 target last raised in August 2025; that latter figure looks increasingly stale given the stock has since more than doubled. The valuation picture is moderate: the stock trades at roughly 17.8x trailing earnings with an EV/EBITDA around 11.6x, both of which have edged slightly higher over the past 30 days in line with the price. Factor scores show strong EPS momentum at the 79th percentile on a 90-day basis and a dividend score at the 97th percentile — a reflection of the company's consistent $0.12 quarterly payout, which was reconfirmed today.
The most interesting comparable from recent history is the February 2026 earnings cycle, when PAHC's last reported quarter drove a 29% one-day move and a 25% five-day move. That was a step-change re-rating event, likely tied to guidance being dramatically lifted or a fundamental inflection. Today's numbers are positive but more incremental — a modest guidance raise rather than a transformative beat. Whether the stock can sustain or extend its run from the mid-$47s in March to above $56 now depends on how the earnings call on May 7 characterises demand trends across animal health and feed additives segments, and whether analysts begin revising targets upward in earnest from levels that are already trailing the tape.
See the live data behind this article on ORTEX.
Open PAHC on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
